CMS has posted the April 2012 Medicare average sales price (ASP) files.  According to CMS, average drug prices in the market remain relatively stable, with prices for the top Part B drugs decreasing by an average of 0.6%. CMS also notes that while it is authorized to substitute average manufacturer price (AMP) for the ASP in certain circumstances (set forth in the final 2012 Medicare physician fee schedule rule), the agency is delaying such substitutions at this time “due to a variety of operational issues.” More information is expected to be released in the future.